Clinical trial NCT07023224: Reliability and Validity Study of the Turkish Version of the Parkinson's Disease Dyskinesia Scale (PDYS-26)
Official title: Adaptation Of The Parkinson's Disease Dyskinesia Questionnaire Into Turkish And Its Validity And Reliability In Parkinson's Patient
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Idiopathic Parkinson Disease
Dyskinesias
Quality of Life
Keywords: Parkinson's disease
Dyskinesia
Parkinson's Disease Dyskinesia Scale
Lead sponsor: Izmir Bakircay University
Sponsor class: OTHER
First posted: 2025-06-15
Enrollment: 130
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study was planned as a methodological research. For this purpose, Parkinson's disease patients who applied to Izmir Çiğli Training and Research Hospital Neurology Outpatient Clinic and met the inclusion criteria will be included in the study. Written informed consent will be obtained from individuals who agree to participate in the study. Based on the commonly recommended participant-to-item ratio in validity and reliability studies (typically 5 to 10 participants per item), the sample size was determined as five times the number of items in the 26-item PDYS-26 scale, and a total of 130 patients with Parkinson's disease were included in the study.

Brief summary: The aim of this methodological study was to investigate the Turkish validity and reliability of the Parkinson's Disease Dyskinesia Scale (PDYS-26).The scale evaluates choreic dyskinesia.Measures the impact of dyskinesia on activities of daily living in patients with Parkinson's disease.

Hypotheses of the Study:

* Parkinson's Disease Dyskinesia Scale (PDYS-26) is reliable in Turkish.
* Parkinson's Disease Dyskinesia Scale (PDYS-26) is valid in Turkish.

To determine the validity of dyskinesia;

* Tampa Kinesiophobia Scale,
* Mini BesTest,
* Activity Specific Balance Safety Scale (ABC) and
* Parkinson's Disease Questionnaire-39 will be evaluated.

Detailed description: In Parkinson's disease, a neurodegenerative disorder affecting the peripheral and central nervous system, dyskinesia is a common symptom that occurs as disease processes progress and leads to disability. The term dyskinesia is a general term that covers many movement disorders. In general, it can be defined as mild to severe abnormal and involuntary muscle movements. In individuals with Parkinson's disease, it is a natural consequence of the neurodegenerative process and a motor complication of the gold standard L-dopa. Assessment of dyskinesia in Parkinson's patients is important for the implementation of appropriate medical, surgical and rehabilitation protocols. There are few scales and patient diaries that clinically assess the effect of interventions for dyskinesia. At the same time, there are deficiencies related to the reliability and validity studies of these existing scales in different languages. Therefore, limitations may arise in the assessment of dyskinesia. For this purpose, our study aims to investigate the reliability and validity of the Parkinson's Disease Dyskinesia Scale (PDYS-26) in Turkish in patients diagnosed with 130 idiopathic Parkinson's patients.In the study, the Parkinson's Disease Dyskinesia Scale (PDYS-26) will be translated into Turkish with the "back translation" method and will be finalized after the approval of the commission consisting of relevant health professionals. The final version of the scale will be applied to Parkinson's patients. To determine the validity of dyskinesia; Tampa Kinesiophobia Scale, Mini BesTest Activity Specific Balance Safety Scale (ABC) and Parkinson's Disease Questionnaire-39 will be evaluated.

Eligibility criteria: Inclusion Criteria:

* Being diagnosed with idiopathic Parkinson's disease
* H\&Y stage 1-3
* UPDRS dyskinesia item score ≥1
* Accepting to participate in the study

Exclusion Criteria:

* Diagnosis of atypical-secondary parkinsonism
* Severe musculoskeletal, neurological and/or cardiopulmonary problems that may affect the results of the assessment
* Mini Mental State Examination score \< 24

Primary outcomes:
measure: (PDYS-26)
timeFrame: Baseline (Day 1) and 7 days post-baseline (Day 8)
Secondary outcomes:
Other outcomes:
measure: Tampa Kinesiophobia Scale
timeFrame: Baseline (Day 1)
measure: (Mini-BesTest)
timeFrame: Baseline (Day 1)
measure: (ABC)
timeFrame: Baseline (Day 1)
measure: (PDQ-39)
timeFrame: Baseline (Day 1)
Locations:
city: İzmir
country: Turkey
facility: Izmir Bakırçay Univercity
city: İ̇zmi̇r
country: Turkey
facility: Bakirçay University Çiğli Regional Education Hospital
Study officials:
affiliation: Izmir Bakircay Univercity
name: Gulbın Ergın, PT, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Katzenschlager R, Schrag A, Evans A, Manson A, Carroll CB, Ottaviani D, Lees AJ, Hobart J. Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure. Neurology. 2007 Aug 7;69(6):555-63. doi: 10.1212/01.wnl.0000266669.18308.af.